TEAD4 and prostate carcinoma: In vitro, silencing of TEAD4 in prostate cancer cells significantly inhibited cell growth (Fig. 7f for CWR22Rv1 and Supplementary Fig. 1g for PC3) and increased the cell doubling time (Fig. 7g).